tucatinib,trastuzumab
seagen
scoop at the esmo wcgc 2022 congress her2+ refractory mcrc treated with tucatinib + trastuzumab: impressive results 
Full Prof Medical Oncology, GI Oncologist
Professeur des Universités - Médecin des Centres Anti-Cancéreux, Chef du Service d'Oncologie Digestive, Gustave Roussy